ClinicalTrials.gg
CompletedNCT05537233ADJUST-T1DUpdated Sep 3, 2025Results posted

ADJUnct Semaglutide Treatment in Type 1 Diabetes

A Phase 2 interventional study of Semaglutide and Placebo in Type 1 Diabetes and Obesity, sponsored by Viral N. Shah. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Viral N. Shah · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing semaglutide in Diabetes Mellitus, Type 1 — 11 open to participants now, 12 under way, 7 of them phase 3. Semaglutide · Diabetes Mellitus, Type 1.

Enrollment
5th of 16
115 · median 60
Started
2023
with 2 others
Phase 2
4 of 16
3 open now
Registered
5th of 16
by date

Among the 16 studies testing semaglutide in Diabetes Mellitus, Type 1, this one is the 5th largest by enrollment, is one of 3 that started in 2023, is one of 4 in phase 2, and was the 5th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

11 of the 16 studies testing semaglutide in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing semaglutide in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.

Read the detailed description

After being informed about the study and potential risks, all patients given written informed consent will undergo a 2-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner using computer generated randomization scheme to receive either semaglutide or placebo (1:1 ratio) for 26 weeks.

03

Conditions studied

  • Type 1 Diabetes
  • Obesity

Keywords

  • Type 1 diabetes
  • Obesity
  • HbA1c
  • Time-in-range
  • Weight loss
  • Cardiovascular risk
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For an eligible subject, all inclusion criteria must be answered "yes"

  1. Age ≥18 and ≤ 65 years
  2. Patients with clinical diagnosis of T1D diagnosed for at least 12 months
  3. Patient is on FDA- approved hybrid closed-loop system for ≥ 3 months
  4. Willing to use once weekly semaglutide
  5. Willing to share devices (HCL system) data uploads
  6. >7.0% and \<10.0%
  7. ≥30 kg/m2
  8. Has current glucagon product to treat severe hypoglycemia
  9. Has current ketone meters to check ketones
  10. Ability to provide before any trial-related activities

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years and >65 years
  2. ≤7.0 % or ≥ 10.0% at screening
  3. Less than 12 months of insulin treatment
  4. Use of unapproved insulin for HCL system. E.g. use of Fiasp in the Tandem Control-IQ system
  5. Not willing to share the devices (HCL system) data uploads
  6. Non compatible devices (e.g. pump, CGM or smart phones) for data transfer
  7. Current use of multiple daily injection or inhaled insulin (Afrezza)
  8. Patients with T1D using any glucose lowering medications other than insulin at the time of screening
  9. Pregnancy, breast feeding, and positive pregnancy test during screening
  10. Women of childbearing age wanting to become pregnant
  11. Unwilling to use acceptable methods (for both men and women) during the trial period
  12. Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (>4 weeks continuously), during the study period
  13. Use of GLP-1RA or weight loss medications in the past 3 month
  14. Clinical diagnosis/history of gastroparesis or gastric motility disorders
  15. Serum triglycerides >500 mg/dL
  16. Planning for bariatric surgery during the study period
  17. below 45 ml/min/1.73 m\^2 using CKD-EPI formula
  18. History of severe hypoglycemia in the previous 3 months
  19. History of diabetic ketoacidosis requiring hospitalization in the past 3 months
  20. History of allergy to any form of insulin, GLP-1RA or its
  21. History of any form of pancreatitis
  22. History of stroke, myocardial infarction in the past 3 months
  23. History of congestive heart failure class III or IV
  24. History of acute or chronic liver disease
  25. History of requiring chemotherapy, surgery or radiation in previous 5 years
  26. Personal or family history of multiple endocrine neoplasia type 2 (MEN-2) or familial thyroid carcinoma or non-familial medullary thyroid carcinoma
  27. Have a pacemaker, metal implants, or aneurysm clips or weigh >330 lbs (exclusion only if doing MRI)
  28. Use of drugs within 5 half-lives prior to screening
  29. Participation to other intervention trials during the study period
  30. Any comorbidities or medical conditions such as severe psychiatric disorder that make a person unfit for the study at the discretion of the investigators
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Participants in this group will receive semaglutide once weekly injection in addition to their standard closed-loop therapy

    Drug: Semaglutide

  • Placebo comparator
    Control

    Participants in this group will receive placebo once weekly injection in addition to their standard closed-loop therapy

    Drug: Placebo

Interventions

  • Semaglutide up to 1 mg per week in addition to standard closed-loop therapy

  • DrugPlacebo

    Injection placebo up to 1 mg per week in addition to standard closed-loop therapy

06

What researchers measure

Primary outcomes

  1. Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group

    Primary outcome will be analyzed per statistical analysis plan using intention to treat basis.

    Time frame: 26 weeks

Secondary outcomes

  1. Change in HbA1c

    HbA1c will be measured at a central laboratory and change in Hba1c from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  2. Change in Mean Glucose

    Mean glucose (mg/dL) will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  3. Percent Time Spent in CGM-measured Glucose Range of 70-140 mg/dL (Time in Tight Target Range; TTIR)

    Percent of time spent in tight glucose range (70-140 mg/dL) will be obtained by CGM and change in percent time in range from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  4. Percent Time Spent in CGM-measured Glucose >180 mg/dL

    Percent of time spent in glucose range \>180 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  5. Percent Time Spent in CGM-measured Glucose >250mg/dL

    Percent of time spent in glucose range \>250 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  6. Percent Time Spent in CGM-measured Glucose <70mg/dL

    Percent of time spent in glucose range \<70 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  7. Change in CGM Measured Glycemic Variability (Coefficient of Variation)

    Glucose coefficient of variation (mg/dL) will be obtained by CGM and change in glucose CV from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

    Time frame: 26 weeks

  8. Change in Weight

    The change in kg of body weight from baseline to 26 weeks will be compared by randomization group using an ITT analysis.

    Time frame: 26 weeks

  9. Change in BMI (Kg/m2)

    Change in body mass index (BMI) calculated as kg body weight per meter squared of height from baseline to 26 weeks will be compared by randomization group using an ITT analysis.

    Time frame: 26 weeks

  10. Severe Hypoglycemia

    SH events in number of patients per group

    Time frame: 26 weeks

Other outcomes

  1. Change in Patient Reported Quality of Life

    Patient reported quality of life will be measured using a validated instrument (ADDQOL) and the change in score from baseline to 26 weeks will be compared by randomization group using an ITT analysis.

    Time frame: 26 weeks

  2. Proportion of Participants With HbA1c <7%

    proportion (N, %) of participants achieving HbA1c \<7% between two groups over 26 weeks

    Time frame: 26 weeks

  3. Proportion of Participants With HbA1c <7.5%

    proportion (N, %) of participants achieving HbA1c \<7.5% between two groups over 26 weeks

    Time frame: 26 weeks

  4. HbA1c Improvement

    HbA1c improvement from baseline to 26 weeks between two groups

    Time frame: 26 weeks

  5. HbA1c Improvement of >0.4% From Baseline

    proportion of participants with HbA1c improvement of \>0.4% from baseline between two groups

    Time frame: 26 weeks

  6. Proportion of Participants Achieving TIR >70%

    Proportion of participants achieving TIR \>70% between two groups over 26 weeks

    Time frame: 26 weeks

  7. Proportion of Participants Achieving TITR >50%

    Proportion of participants achieving TITR (time in 70-140 mg/dL) \>50% between two groups

    Time frame: 26 weeks

  8. Proportion of Participants Achieving TIR >80%

    Proportion of participants achieving TIR \>80% between two groups

    Time frame: 26 weeks

  9. Proportion of Participants Achieving TITR >60%

    Proportion of participants achieving TITR (time in 70-140 mg/dL) \>60% between two groups

    Time frame: 26 weeks

  10. Number of TBR<70 Events

    Numbers of events of CGM glucose \<70 mg/dL lasting for at least 15 minutes between two groups

    Time frame: 26 weeks

  11. Number of TBR <54 Events

    Numbers of events of CGM glucose \<54mg/dL lasting for at least 15 minutes between two groups

    Time frame: 26 weeks

  12. Change in Total Daily Dose of Insulin (TDD, Units Per Day and U/Kg/Day)

    Change in TDD between two groups

    Time frame: 26 weeks

  13. Proportion Achieving Weight Loss ≥5%

    Proportion of participants achieving weight loss ≥5% from baseline between two groups

    Time frame: 26 weeks

  14. Proportion Achieving Weight Loss ≥10%

    Proportion of participants achieving weight loss ≥10% from baseline between two groups

    Time frame: 26 weeks

  15. Proportion of Achieving BMI <30 kg/m2

    Proportion of participants achieving BMI \<30 kg/m2 between two groups

    Time frame: 26 weeks

  16. Proportion of Achieving BMI <25 kg/m2

    Proportion of participants achieving BMI \<25 kg/m2 between two groups

    Time frame: 26 weeks

  17. Change in Systolic Blood Pressure (SBP)

    change in SBP (mmHg) between two groups

    Time frame: 26 weeks

  18. Change in Diastolic Blood Pressure (DBP)

    change in DBP (mmHg) between two groups

    Time frame: 26 weeks

  19. Change in Pulse Pressure

    change in pulse pressure between two groups

    Time frame: 26 weeks

  20. Change in Triglyceride/HDL Ratio

    Change in triglyceride/HDL ratio between two groups

    Time frame: 26 weeks

  21. Change in Brach D

    Change in brachial arterial distensibility between two groups

    Time frame: 26 weeks

  22. Change in Carotid Intima Media Thickness (cIMT)

    Change in carotid intima media thickness (cIMT) between two groups

    Time frame: 26 weeks

  23. Change in Femoral to Carotid Pulse Wave Velocity (m/s)

    Change in femoral to carotid pulse wave velocity (m/s) between two groups

    Time frame: 26 weeks

  24. Change in Urine Albumin to Creatinine Ratio (ACR)

    Change in ACR between two groups

    Time frame: 26 weeks

  25. Quality of Life (Diabetes Dependent QOL)

    Change in QOL between two groups

    Time frame: 26 weeks

  26. Change in CGM Metrics by Daytime vs Nighttime

    Change in CGM metrics (TIR, TITR, mean glucose, TBR, TAR \>180, SD, CV) by daytime (6 AM to \<11 PM) and nighttime (11 PM to \<6 AM) between two groups

    Time frame: 26 weeks

  27. AID Setting Adjustment

    Defined any adjustment in settings by provider or patient per person over the study period by two groups (number of adjustments (N) during trial) between two groups

    Time frame: 26 weeks

  28. Change in Basal Insulin Per Day

    Change in basal insulin per day (Total basal insulin including autobasal delivery, units per day and U/kg/day) between two groups

    Time frame: 26 weeks

  29. Change in Total Boluses Per Day

    Change in total boluses per day (frequency of boluses per day) between two groups

    Time frame: 26 weeks

  30. Achievement of Primary Outcome and Key Secondary Outcomes by Types of AID Systems

    Proportion of participants achieving primary outcome and key secondary glycemic outcomes by types of AID systems

    Time frame: 26 weeks

  31. Change in Carbohydrate Intake Per Day (Grams/Day)

    Change in Carbohydrate intake per day (grams/day) between two groups

    Time frame: 26 weeks

  32. Change in Total Bolus Insulin Per Day

    Change in total bolus insulin per day (units per day and U/Kg/day) between two groups

    Time frame: 26 weeks

  33. Change in eGFR

    Change in eGFR using CKD-EPI between two groups

    Time frame: 26 weeks

  34. Change in Fib-4 Score

    Change in Fib-4 score between two groups

    Time frame: 26 weeks

  35. Change in HSI (Hepatic Steatosis Index)

    Change in HSI (hepatic steatosis index) between two groups

    Time frame: 26 weeks

  36. Change in MRI Measured Pulse Wave Velocity and Longitudinal Strain

    Change in MRI measured pulse wave velocity and longitudinal strain between two groups

    Time frame: 26 weeks

  37. Change in LDL-C

    Change in LDL-C between two groups

    Time frame: 26 weeks

  38. Change in TC

    Change in TC between two groups

    Time frame: 26 weeks

  39. Change in TG

    Change in TG between two groups

    Time frame: 26 weeks

  40. Change in HDL-C

    Change in HDL-C between two groups

    Time frame: 26 weeks

  41. Proportion With ACR <30 at 26 Weeks

    Proportion of participants with ACR \<30 at 26 weeks between two groups

    Time frame: 26 weeks

  42. Proportion With Change in ACR From >30 to <30

    Proportion of participants with change in ACR from \>30 to \<30 between two groups

    Time frame: 26 weeks

  43. Achievement of Primary Outcomes by Baseline BMI (BMI <35 vs >35)

    Achievement of primary outcomes by baseline BMI (BMI \<35 vs \>35)

    Time frame: 26 weeks

  44. Achievement of Primary Outcomes by Baseline A1c (A1c <7.5% vs >7.5%)

    Achievement of primary outcomes by baseline A1c (A1c \<7.5% vs \>7.5%)

    Time frame: 26 weeks

07

Results

Posted Aug 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneSemaglutideControl
Started3636
Completed3433
Not completed23

Outcome measures

PrimaryProportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group

Primary outcome will be analyzed per statistical analysis plan using intention to treat basis.

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group
ParticipantsSemaglutideControl
Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group130
SecondaryChange in HbA1c

HbA1c will be measured at a central laboratory and change in Hba1c from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · percentage HbA1c
Change in HbA1c
percentage HbA1cSemaglutideControl
Change in HbA1c-0.7 ± 0.1-0.4 ± 0.1
SecondaryChange in Mean Glucose

Mean glucose (mg/dL) will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · mg/dL
Change in Mean Glucose
mg/dLSemaglutideControl
Change in Mean Glucose-15.7 ± 2.6-3.6 ± 2.8
SecondaryPercent Time Spent in CGM-measured Glucose Range of 70-140 mg/dL (Time in Tight Target Range; TTIR)

Percent of time spent in tight glucose range (70-140 mg/dL) will be obtained by CGM and change in percent time in range from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · percentage of time
Percent Time Spent in CGM-measured Glucose Range of 70-140 mg/dL (Time in Tight Target Range; TTIR)
percentage of timeSemaglutideControl
Percent Time Spent in CGM-measured Glucose Range of 70-140 mg/dL (Time in Tight Target Range; TTIR)9.8 ± 1.72.9 ± 1.8
SecondaryPercent Time Spent in CGM-measured Glucose >180 mg/dL

Percent of time spent in glucose range \>180 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · percentage
Percent Time Spent in CGM-measured Glucose >180 mg/dL
percentageSemaglutideControl
Percent Time Spent in CGM-measured Glucose >180 mg/dL-11.1 ± 1.8-2.7 ± 1.9
SecondaryPercent Time Spent in CGM-measured Glucose >250mg/dL

Percent of time spent in glucose range \>250 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · percentage
Percent Time Spent in CGM-measured Glucose >250mg/dL
percentageSemaglutideControl
Percent Time Spent in CGM-measured Glucose >250mg/dL-5.1 ± 1.1-0.5 ± 1.2
SecondaryPercent Time Spent in CGM-measured Glucose <70mg/dL

Percent of time spent in glucose range \<70 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · percentage
Percent Time Spent in CGM-measured Glucose <70mg/dL
percentageSemaglutideControl
Percent Time Spent in CGM-measured Glucose <70mg/dL0.1 ± 0.20.4 ± 0.2
SecondaryChange in CGM Measured Glycemic Variability (Coefficient of Variation)

Glucose coefficient of variation (mg/dL) will be obtained by CGM and change in glucose CV from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · percentage
Change in CGM Measured Glycemic Variability (Coefficient of Variation)
percentageSemaglutideControl
Change in CGM Measured Glycemic Variability (Coefficient of Variation)-0.3 ± 0.80.9 ± 0.9
SecondaryChange in Weight

The change in kg of body weight from baseline to 26 weeks will be compared by randomization group using an ITT analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · kg
Change in Weight
kgSemaglutideControl
Change in Weight-9.2 ± 0.7-0.4 ± 0.6
SecondaryChange in BMI (Kg/m2)

Change in body mass index (BMI) calculated as kg body weight per meter squared of height from baseline to 26 weeks will be compared by randomization group using an ITT analysis.

Time frame:
26 weeks
Reported as:
Least squares mean · kg/m2
Change in BMI (Kg/m2)
kg/m2SemaglutideControl
Change in BMI (Kg/m2)-3.3 ± 0.3-0.2 ± 0.2
SecondarySevere Hypoglycemia

SH events in number of patients per group

Time frame:
26 weeks
Reported as:
Count of participants · Participants
Severe Hypoglycemia
ParticipantsSemaglutideControl
Severe Hypoglycemia22
Other pre-specifiedChange in Patient Reported Quality of Life

Patient reported quality of life will be measured using a validated instrument (ADDQOL) and the change in score from baseline to 26 weeks will be compared by randomization group using an ITT analysis.

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Participants With HbA1c <7%

proportion (N, %) of participants achieving HbA1c \<7% between two groups over 26 weeks

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Participants With HbA1c <7.5%

proportion (N, %) of participants achieving HbA1c \<7.5% between two groups over 26 weeks

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedHbA1c Improvement

HbA1c improvement from baseline to 26 weeks between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedHbA1c Improvement of >0.4% From Baseline

proportion of participants with HbA1c improvement of \>0.4% from baseline between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Participants Achieving TIR >70%

Proportion of participants achieving TIR \>70% between two groups over 26 weeks

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Participants Achieving TITR >50%

Proportion of participants achieving TITR (time in 70-140 mg/dL) \>50% between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Participants Achieving TIR >80%

Proportion of participants achieving TIR \>80% between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Participants Achieving TITR >60%

Proportion of participants achieving TITR (time in 70-140 mg/dL) \>60% between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedNumber of TBR<70 Events

Numbers of events of CGM glucose \<70 mg/dL lasting for at least 15 minutes between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedNumber of TBR <54 Events

Numbers of events of CGM glucose \<54mg/dL lasting for at least 15 minutes between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Total Daily Dose of Insulin (TDD, Units Per Day and U/Kg/Day)

Change in TDD between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion Achieving Weight Loss ≥5%

Proportion of participants achieving weight loss ≥5% from baseline between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion Achieving Weight Loss ≥10%

Proportion of participants achieving weight loss ≥10% from baseline between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Achieving BMI <30 kg/m2

Proportion of participants achieving BMI \<30 kg/m2 between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion of Achieving BMI <25 kg/m2

Proportion of participants achieving BMI \<25 kg/m2 between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Systolic Blood Pressure (SBP)

change in SBP (mmHg) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Diastolic Blood Pressure (DBP)

change in DBP (mmHg) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Pulse Pressure

change in pulse pressure between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Triglyceride/HDL Ratio

Change in triglyceride/HDL ratio between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Brach D

Change in brachial arterial distensibility between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Carotid Intima Media Thickness (cIMT)

Change in carotid intima media thickness (cIMT) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Femoral to Carotid Pulse Wave Velocity (m/s)

Change in femoral to carotid pulse wave velocity (m/s) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Urine Albumin to Creatinine Ratio (ACR)

Change in ACR between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedQuality of Life (Diabetes Dependent QOL)

Change in QOL between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in CGM Metrics by Daytime vs Nighttime

Change in CGM metrics (TIR, TITR, mean glucose, TBR, TAR \>180, SD, CV) by daytime (6 AM to \<11 PM) and nighttime (11 PM to \<6 AM) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedAID Setting Adjustment

Defined any adjustment in settings by provider or patient per person over the study period by two groups (number of adjustments (N) during trial) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Basal Insulin Per Day

Change in basal insulin per day (Total basal insulin including autobasal delivery, units per day and U/kg/day) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Total Boluses Per Day

Change in total boluses per day (frequency of boluses per day) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedAchievement of Primary Outcome and Key Secondary Outcomes by Types of AID Systems

Proportion of participants achieving primary outcome and key secondary glycemic outcomes by types of AID systems

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Carbohydrate Intake Per Day (Grams/Day)

Change in Carbohydrate intake per day (grams/day) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Total Bolus Insulin Per Day

Change in total bolus insulin per day (units per day and U/Kg/day) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in eGFR

Change in eGFR using CKD-EPI between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in Fib-4 Score

Change in Fib-4 score between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in HSI (Hepatic Steatosis Index)

Change in HSI (hepatic steatosis index) between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in MRI Measured Pulse Wave Velocity and Longitudinal Strain

Change in MRI measured pulse wave velocity and longitudinal strain between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in LDL-C

Change in LDL-C between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in TC

Change in TC between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in TG

Change in TG between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedChange in HDL-C

Change in HDL-C between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion With ACR <30 at 26 Weeks

Proportion of participants with ACR \<30 at 26 weeks between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedProportion With Change in ACR From >30 to <30

Proportion of participants with change in ACR from \>30 to \<30 between two groups

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedAchievement of Primary Outcomes by Baseline BMI (BMI <35 vs >35)

Achievement of primary outcomes by baseline BMI (BMI \<35 vs \>35)

Time frame:
26 weeks

Results for this outcome have not been posted.

Other pre-specifiedAchievement of Primary Outcomes by Baseline A1c (A1c <7.5% vs >7.5%)

Achievement of primary outcomes by baseline A1c (A1c \<7.5% vs \>7.5%)

Time frame:
26 weeks

Results for this outcome have not been posted.

Adverse events

Collected over from signing consent from till end of the study (i.e 26 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide0/36 (0%)1/36 (2.8%)26/36 (72.2%)
Control0/36 (0%)0/36 (0%)11/36 (30.6%)
Most frequent serious events
Most frequent serious events
EventSemaglutideControl
Nausea & vomitingGastrointestinal disorders1/360/36
Most frequent other events
Most frequent other events
EventSemaglutideControl
Gastrointestinal eventsGastrointestinal disorders19/369/36
COVID-19Infections and infestations4/361/36
Upper respitory infectinInfections and infestations3/361/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)SemaglutideControlTotal
Mean41.4 ± 11.638.9 ± 13.140 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)SemaglutideControlTotal
Female222042
Male141630
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SemaglutideControlTotal
Hispanic or Latino145
Not Hispanic or Latino353267
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SemaglutideControlTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American336
White333063
More than one race000
Unknown or Not Reported022
body mass index
body mass index(kg/m2)SemaglutideControlTotal
Mean34.7 ± 3.936.0 ± 5.235 ± 4.5
HbA1c
HbA1c(%)SemaglutideControlTotal
Mean7.8 ± 0.67.7 ± 0.67.8 ± 0.6
Diabetes Duration
Diabetes Duration(years)SemaglutideControlTotal
Mean23.4 ± 11.221.9 ± 11.623 ± 11
08

Study locations

4 sites
  • Barbara Davis Center for Diabetes
    Aurora, Colorado 80045, United States
  • Iowa Diabetes Research Center
    West Des Moines, Iowa 50265, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Harold Schnitzer Diabetes Health Center
    Portland, Oregon 97239, United States
09

References and documents

Publications

  • Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug;4(8):EVIDoa2500173. doi: 10.1056/EVIDoa2500173. Epub 2025 Jun 23. PubMed 40550013 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD may be available once the study is completed and all results are published.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Aug 2024, 15 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 15 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Sep 13, 2022
StartActual
Apr 11, 2023
Primary completionActual
Aug 6, 2024
CompletionActual
Aug 6, 2024
Results first posted
Aug 12, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05537233
Lead sponsor
Viral N. Shah
Collaborators
Juvenile Diabetes Research Foundation
Responsible party
Viral N. Shah (Professor of Medicine, Division of Endocrinology & Metabolism, Indiana University) — Sponsor-investigator
First posted
Sep 13, 2022
Start date
Apr 11, 2023
Primary completion
Aug 6, 2024
Completion
Aug 6, 2024
Results posted
Aug 12, 2025
Last update
Sep 3, 2025

Study contacts

Viral N Shah, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion